Facebook Live Recording - Control-IQ™ Technology for the t:slim X2™ Insulin Pump

This Facebook Live was hosted Wednesday January 15 at 4pm EST/ 1pm PST featuring Danielle Karsten, Director of Product Marketing at Tandem Diabetes Care. The video gives an overview of Control-IQ™ technology, as well as outlines the process of getting it for both new customers and current t:slim X2™ insulin pump users.

The event was moderated by Marketing Manager Christopher Angell, and was followed by a brief live Q&A.

Important Safety Information:

Caution: Federal (USA) law restricts the t:slim X2 insulin pump and Control-IQ technology to sale by or on the order of a physician.

Indications for Use:

t:slim X2 insulin pump
The t:slim X2 insulin pump with interoperable technology is an alternate controller enabled (ACE) pump that is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in individuals 6 years of age and greater. The pump is intended for single patient, home use and requires a prescription. The pump is indicated for use with NovoLog or Humalog U-100 insulin.

Control-IQ technology
Control-IQ technology is intended for use with a compatible integrated continuous glucose monitor (iCGM, sold separately) and ACE pump to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons 14 years of age and greater. Control-IQ technology is intended for single patient use. Control-IQ technology is indicated for use with NovoLog or Humalog U-100 insulin.

Contraindications and Warnings:
WARNING: Control-IQ technology should not be used by anyone under the age of six years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 55 pounds.

Control-IQ technology is not indicated for use in pregnant women, people on dialysis, or critically ill patients.

Users of the t:slim X2 pump and Control-IQ technology must:
• be able and willing to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use;
• test blood glucose levels as recommended by their healthcare provider;
• demonstrate adequate carb-counting skills;
• maintain sufficient diabetes self-care skills;
• see healthcare provider(s) regularly; and
• have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders;

The t:slim X2 pump, transmitter, and sensor must be removed before MRI, CT, or diathermy treatment. For additional important safety information, visit tandemdiabetes.com/safetyinfo

© 2020 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care is a registered trademark and Control-IQ, t:simulator, and t:slim X2 are trademarks of Tandem Diabetes Care, Inc. All third-party marks are the property of their respective owners.